Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.67 |
| ▸ | TPO | P07202 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14936667 | 0.94 | MPO (0.63) | MPOTPOGFERHSD17B10L3MBTL1 | |
| SCHEMBL14947124 | 0.90 | MPO (0.76) | MPOTPOGFERHSD17B10L3MBTL1 | |
| SCHEMBL14936554 | 0.88 | MPO (0.74) | MPOTPO | |
| SCHEMBL14947076 | 0.87 | MPO (0.73) | MPOTPOHSD17B10ALDH1A1 | |
| SCHEMBL14946918 | 0.86 | MPO (0.72) | MPOTPOALDH1A1 | |
| SCHEMBL14936296 | 0.85 | MPO (0.76) | MPOTPOHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL14936412 | 0.84 | MPO (0.75) | MPOTPOHSD17B10ALDH1A1 | |
| SCHEMBL14947026 | 0.84 | MPO (0.74) | MPOTPOALDH1A1 | |
| SCHEMBL14947085 | 0.83 | MPO (0.67) | MPOTPOHSD17B10ALDH1A1 | |
| SCHEMBL14947084 | 0.83 | MPO (0.67) | MPOTPOHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20140288049-A1 | 2-Thiopyrimidinones | PFIZER (US) | 2014-09-25 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835449-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| WO-2013068875-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013068875-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123230-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GFER 2098/4885 |
| US-20160304469-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GFER 2098/4885 |
| US-20140288049-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GFER 2098/4885 |
| US-20130296351-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GFER 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.